2-(2-chloro-5-nitrophenyl)oxazolo[4,5-b]pyridine | 423755-09-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2-chloro-5-nitrophenyl)oxazolo[4,5-b]pyridine
• 英文别名: 2-(2-chloro-5-nitro-phenyl)-oxazolo[4,5-b]pyridine；2-(2-chloro-5-nitrophenyl)-[1,3]oxazolo[4,5-b]pyridine
• CAS: 423755-09-3
• 化学式: C₁₂H₆ClN₃O₃
• 分子量: 275.651
• InChiKey: KNXSPWLWIMBTNI-UHFFFAOYSA-N

物化性质

• 沸点：
  412.6±40.0 °C(Predicted)
• 密度：
  1.515±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  19
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.7
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-chloro-5-nitrophenyl)oxazolo[4,5-b]pyridine 在 4-二甲氨基吡啶 、 tin(II) chloride dihdyrate 作用下， 以 吡啶 、 乙酸乙酯 为溶剂， 生成 N-(4-chloro-3-(oxazolo[4,5-b]pyridin-2-yl)phenyl)-2,2,2-trifluoroacetamide
  参考文献：
  名称：

  Substituted 2-Phenylimidazopyridines: A New Class of Drug Leads for Human African Trypanosomiasis

  摘要：

  A phenotypic screen of a compound library for antiparasitic activity on Trypanosoma brucei, the causative agent of human African trypanosomiasis, led to the identification of substituted 2-(3-aminophenyl)oxazolopyridines as a starting point for hit-to-lead medicinal chemistry. A total of 110 analogues were prepared, which led to the identification of 64, a substituted 2-(3-aminophenyl)imidazopyridine. This compound showed antiparasitic activity in vitro with an EC50 of 2 nM and displayed reasonable druglike properties when tested in a number of in vitro assays. The compound was orally bioavailable and displayed good plasma and brain exposure in mice. Compound 64 cured mice infected with Trypanosorna brucei when dosed orally down to 2.5 mg/kg. Given its potent antiparasitic properties and its ease of synthesis, compound 64 represents a new lead for the development of drugs to treat human African trypanosomiasis.

  DOI：

  10.1021/jm401178t
• 作为产物：
  描述：

  2-氨基-3-羟基吡啶 、 2-氯-5-硝基苯甲酸 在 polyphosphoric acid 作用下， 反应 5.0h， 以51%的产率得到2-(2-chloro-5-nitrophenyl)oxazolo[4,5-b]pyridine
  参考文献：
  名称：

  Substituted 2-Phenylimidazopyridines: A New Class of Drug Leads for Human African Trypanosomiasis

  摘要：

  A phenotypic screen of a compound library for antiparasitic activity on Trypanosoma brucei, the causative agent of human African trypanosomiasis, led to the identification of substituted 2-(3-aminophenyl)oxazolopyridines as a starting point for hit-to-lead medicinal chemistry. A total of 110 analogues were prepared, which led to the identification of 64, a substituted 2-(3-aminophenyl)imidazopyridine. This compound showed antiparasitic activity in vitro with an EC50 of 2 nM and displayed reasonable druglike properties when tested in a number of in vitro assays. The compound was orally bioavailable and displayed good plasma and brain exposure in mice. Compound 64 cured mice infected with Trypanosorna brucei when dosed orally down to 2.5 mg/kg. Given its potent antiparasitic properties and its ease of synthesis, compound 64 represents a new lead for the development of drugs to treat human African trypanosomiasis.

  DOI：

  10.1021/jm401178t

文献信息

• Benzoxazole LPAAT-B inhibitors and uses thereof
  申请人：CELL THERAPEUTICS, INC.

  公开号：US20020107269A1

  公开（公告）日：2002-08-08

  The invention relates to benzoxazoles and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening for LPAAT-&bgr; activity.

  该发明涉及苯并噁唑及其用途，用于抑制溶磷脂酸酰基转移酶β（LPAAT-β）活性。该发明还涉及使用所述苯并噁唑治疗癌症的方法。该发明还涉及筛选LPAAT-β活性的方法。
• [EN] BENZOXAZOLE LPAAT- beta INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS BENZOXAZOLES DE LPAAT- DOLLAR G(B) ET UTILISATIONS ASSOCIEES
  申请人：BONHAM LYNN

  公开号：WO2002036580A2

  公开（公告）日：2002-05-10

  The invention relates to benzoxazoles of the following Formula, wherein the variables are defined in the claims and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening to LPAAT-β activitiy.
• [EN] BENZOXAZOLE LPAAT- BETA INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS BENZOXAZOLES DE LPAAT- DOLLAR G(B) ET UTILISATIONS ASSOCIEES
  申请人：——

  公开号：WO2002036580A9

  公开（公告）日：2003-02-13

  [EN] The invention relates to benzoxazoles of the following Formula, wherein the variables are defined in the claims and the use thereof to inhibit lysophosphatidic acid acyltransferase beta (LPAAT- beta ) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening to LPAAT- beta activitiy.
  [FR] L'invention concerne des benzoxazoles et l'utilisation de ceux-ci dans l'inhibition de l'activité de l'acide lysophosphatidique de l'acyltransférase beta (LPAAT- beta ). L'invention concerne en outre des méthodes de traitement de cancer mettant en oeuvre ces benzoxazoles. L'invention concerne enfin des méthodes de criblage de l'activité de LPAAT- beta .
• Substituted 2-Phenylimidazopyridines: A New Class of Drug Leads for Human African Trypanosomiasis
  作者：Hari Babu Tatipaka、J. Robert Gillespie、Arnab K. Chatterjee、Neil R. Norcross、Matthew A. Hulverson、Ranae M. Ranade、Pendem Nagendar、Sharon A. Creason、Joshua McQueen、Nicole A. Duster、Advait Nagle、Frantisek Supek、Valentina Molteni、Tanja Wenzler、Reto Brun、Richard Glynne、Frederick S. Buckner、Michael H. Gelb

  DOI：10.1021/jm401178t

  日期：2014.2.13

  A phenotypic screen of a compound library for antiparasitic activity on Trypanosoma brucei, the causative agent of human African trypanosomiasis, led to the identification of substituted 2-(3-aminophenyl)oxazolopyridines as a starting point for hit-to-lead medicinal chemistry. A total of 110 analogues were prepared, which led to the identification of 64, a substituted 2-(3-aminophenyl)imidazopyridine. This compound showed antiparasitic activity in vitro with an EC50 of 2 nM and displayed reasonable druglike properties when tested in a number of in vitro assays. The compound was orally bioavailable and displayed good plasma and brain exposure in mice. Compound 64 cured mice infected with Trypanosorna brucei when dosed orally down to 2.5 mg/kg. Given its potent antiparasitic properties and its ease of synthesis, compound 64 represents a new lead for the development of drugs to treat human African trypanosomiasis.